Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848912 | 0.83 | SLC27A1 (0.36) | SLC27A1TRPV1HPGDMEN1HTT | |
| SCHEMBL12848446 | 0.81 | HPGD (0.37) | SLC27A1HPGDHTTHPGDSHSD17B10 | |
| SCHEMBL12848901 | 0.81 | TP53 (0.38) | SLC27A1ALOX15HTTHSD17B10MAPT | |
| SCHEMBL12848839 | 0.73 | SLC27A1 (0.36) | SLC27A1TRPV1HRH3HPGDHTT | |
| SCHEMBL12848562 | 0.68 | TP53 (0.37) | ALOX15TSHRMEN1HTTHSD17B10 | |
| SCHEMBL12848903 | 0.67 | TRPV1 (0.39) | SLC27A1TRPV1HPGDHSD17B10 | |
| SCHEMBL12848445 | 0.66 | MEN1 (0.38) | SLC27A1TRPV1HPGDMEN1HTT | |
| SCHEMBL12848741 | 0.65 | HTR1F (0.38) | SLC27A1TRPV1MAPT | |
| SCHEMBL12848841 | 0.65 | MAPT (0.37) | MAPT | |
| SCHEMBL11075066 | 0.64 | GRM5 (0.51) | SLC27A1HRH3HPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | SLC27A1 2097/4885TRPV1 220/4885HRH3 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.